RNS Number : 2916J
OptiBiotix Health PLC
20 May 2025

OptiBiotix Health plc
("OptiBiotix" or the "Company" or "the Group")

Launch of SlimBiome® products with NASDAQ listed US partner

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes, announces the launch of products containing SlimBiome® with a NASDAQ listed partner, Natural Health Trends Corp (NASDAQ: NHTC) ("NHT").

NHT is an international direct selling and ecommerce company operating through its subsidiaries throughout Asia, the Americas, and Europe. The Company markets premium quality products under the NHT global brand. The product, which was produced and shipped in final product format by OptiBiotix is a Tomato Soup formulation, TwinSlim Tomato Soup,developed specifically for NHT and its global markets. The product has been launched in Hong Kong for the Chinese market with the product shipped for launch in the USA in the upcoming weeks. OptiBiotix has been involved in presentations to NHT's Asian distributors and filming videos explaining the science and benefits of SlimBiome® for both the Asian and USA markets.

This is the second USA partner launching SlimBiome® products in the last few months, with a third, one of the USA's leading weight management brands, expected to launch in the near future. This is all part of the Company's strategy to develop and market clinically proven and patented products with functional benefits (for SlimBiome®: reduce hunger and food cravings) and grow our business in the high growth markets of Asia, particularly India, and the large USA market, through a mix of ingredient and finished products sold by brand owners, specialised distributors and e-commerce channels. OptiBiotix is now beginning to see returns from the investments made in clinical studies, intellectual property, and more recently supporting partners in their marketing at a time when the anti-obesity drugs have enhanced consumer awareness of the benefits of appetite suppression in weight management. We are now seeing regular launches of SlimBiome® products with larger partners in more countries around the world, enhancing brand recognition and creating greater interest. The focus now is on increasing the number of large partners and delivering regular repeat orders to reach group profitability.

Stephen O'Hara, CEO of OptiBiotix Health plc said: *"We are pleased to announce the launch of SlimBiome® containing products with a well-known global brand like NHT. TwinSlim Tomato soup was developed specifically for NHT to create a healthy snack which reduces hunger and food cravings and meets the needs of Asian and US markets and extends the range of products containing SlimBiome® in the USA and Asia markets. This is part of a growing trend to incorporate science backed functional ingredients into everyday products."*

"As the dynamics continue to change in the weight management industry, brought about by the anti-obesity drugs, SlimBiome®'s IP and human studies are meeting a developing market need for added functionality in weight management products. More specifically, following the launch of the anti-obesity drugs, natural non-drug alternatives to reduce hunger and cravings are actively being sought by consumers. This announcement demonstrates that the science and multiple human studies carried out on SlimBiome® is now attracting the interest of well-known health brands around the world."

The Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

OptiBiotix Health plc www.optibiotix.com
Neil Davidson, Chairman *Contact via Walbrook below*
Stephen O'Hara, Chief Executive

Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti

Peterhouse Capital Limited (Broker) Tel: 020 7220 9797
Duncan Vasey / Lucy Williams

Walbrook PR Ltd
Anna Dunphy Mob: 07876 741 001

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

Forward-Looking Statements
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCUKSNRVUUVAAR